Who
Graham K. Cooper
Director
Company insider
Files Form 4 as: Director, Beam Therapeutics; Director, Kezar Life Sciences; Director, Applied Molecular Transport; Director, Unity Biotechnology; Director, Nuvation Bio; Officer, Assembly Biosciences; Chief Financial Officer, Receptos; Director, Celladon.
In numbers
- Trades disclosed
- 169
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $5.7M
- Companies
- 10
- Companies where not an officer
- 6
- First trade
- 20 Nov 2007
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,742 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —3,742 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —889 at $0.00 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Graham K. Cooper; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.